Please ensure Javascript is enabled for purposes of website accessibility

Why Anacor Pharmaceuticals Inc. Stock Briefly Dipped

By Sean Williams - Jul 8, 2014 at 2:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Anacor dips despite the FDA approving a key drug. Find out why investors panicked following this approval.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Anacor Pharmaceuticals (NASDAQ: ANAC), a biopharmaceutical company focused on developing anti-fungal and anti-inflammatory medications, briefly dipped as much as 11% this morning following the Food and Drug Administration's approval of Kerydin as a treatment for onychomycosis of the toenails. Shares have since recovered and are now down just 1% as of this writing.

So what?: According to Anacor's early morning press release, the FDA has approved its topical solution known as Kerydin to treat a fungal infection of the toenail and nail bed that's found in approximately 35 million people in the U.S. According to Anacor's CEO Paul Berns "We expect to launch KERYDIN in the U.S., either alone or with a partner, as early as the end of this quarter." Based on a previous investor presentation from Anacor, the company believes Kerydin could have peak sales potential of beyond $1 billion.

Now what?: Normally we see a company move higher on an FDA approval, but two factors appear to be playing into today's drop. First, Anacor has rocketed higher in anticipation of this approval with shares rising from just $6 to yesterday's closing price of $16.74. In other words, it's not as if the market hasn't already factored in some of the optimism surrounding Kerydin. The other factor at work here is Berns' commentary about finding a partner. I suspect some investors are disappointed that the smaller Anacor has yet to find an established partner for its drug and they're worried about launch and execution risk. Personally, I'm excited for Anacor and its shareholders, but I share both of these aforementioned concerns. I'd stick to the sidelines and wait for Anacor to get a few quarters of sales under its belt before even considering the idea of chasing this stock any higher.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.